tiprankstipranks
Trending News
More News >
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
US Market
Advertisement

Arcutis Biotherapeutics (ARQT) Ownership - Who Owns Arcutis Biotherapeutics?

Compare
880 Followers

Arcutis Biotherapeutics (ARQT) Ownership Overview

9.86%17.77%55.84%12.23%4.29%
55.84% Other Institutional Investors
12.23% ETFs
4.29% Public Companies and Individual Investors
The ownership structure of Arcutis Biotherapeutics (ARQT) stock is a mix of institutional, retail, and individual investors. Approximately 85.84% of the company’s stock is owned by Institutional Investors, 9.86% is owned by Insiders, and 4.29% is owned by Public Companies and Individual Investors.
The ownership structure of Arcutis Biotherapeutics (ARQT) stock is a mix of institutional, retail, and individual investors. Approximately 73.61% of the company’s stock is owned by Institutional Investors, 9.86% is owned by Insiders, and 12.23% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 21, 2025
xxxxxxxxxxxxx
$28280
Aug 05, 2025
xxxxxxxxxxxxx
$165353
Aug 05, 2025
xxxxxxxxxxxxx
$37547
Aug 05, 2025
xxxxxxxxxxxxx
$1274

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$162043
Jun 30, 2025
xxxxxxxxxxxxx
$1004112
Jun 30, 2025
xxxxxxxxxxxxx
$2881250
Jun 30, 2025
xxxxxxxxxxxxx
$5251050

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,862,862Insider7.39%153,238,884
5,578,063Institution4.65%96,444,709
5,120,740Institution4.27%88,537,595
4,797,433Institution4.00%82,947,617
4,155,763Institution3.47%71,853,142
3,159,143Institution2.63%54,621,582
2,269,514Institution1.89%39,239,897
2,168,102Institution1.81%37,486,484
1,358,500Institution1.13%23,488,465
1,334,049Institution1.11%23,065,707

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
5,120,740Institution4.27%88,537,595
3,159,143Institution2.63%54,621,582
2,269,514Institution1.89%39,239,897
1,334,049Institution1.11%23,065,707
1,182,387Institution0.99%20,443,471
1,059,496Institution0.88%18,318,686
965,545Institution0.81%16,694,273
822,815Institution0.69%14,226,471
641,226Institution0.53%11,086,798
579,576Institution0.48%10,020,869

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,390,371Institution2.83%49,431,609
2,667,207Institution2.22%46,116,009
1,952,849Institution1.63%34,545,899
1,153,304Institution0.96%16,815,172
944,259Institution0.79%16,326,238
635,406Institution0.53%10,986,170
510,293Institution0.43%7,440,072
507,132Institution0.42%8,971,165
330,058Institution0.28%4,812,246
289,025Institution0.24%4,359,525

FAQ

Who Owns Arcutis Biotherapeutics (ARQT)?
According to the latest TipRanks data, approximately 55.84% of the company's stock is held by institutional investors, 9.86% is held by insiders, and 4.29% is held by retail investors.
    What percentage of Arcutis Biotherapeutics (ARQT) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 55.84% of Arcutis Biotherapeutics (ARQT) stock is held by institutional investors.
      What percentage of Arcutis Biotherapeutics (ARQT) stock is held by retail investors?
      According to the latest TipRanks data, approximately 4.29% of Arcutis Biotherapeutics (ARQT) stock is held by retail investors.
        Who owns the most shares of Arcutis Biotherapeutics (ARQT)?
        Patrick Heron owns the most shares of Arcutis Biotherapeutics (ARQT).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis